PMID- 14637261
OWN - NLM
STAT- MEDLINE
DCOM- 20040714
LR  - 20220311
IS  - 0009-8981 (Print)
IS  - 0009-8981 (Linking)
VI  - 338
IP  - 1-2
DP  - 2003 Dec
TI  - Atorvastatin reduces plasma MCP-1 in patients with acute coronary syndrome.
PG  - 17-24
AB  - BACKGROUND: The monocyte chemoattractant protein-1 (MCP-1) is a chemokine 
      responsible for the recruitment of monocytes to sites of inflammation. MCP-1 may 
      play critical roles in plaque instability. Anti-inflammation may be one benefit 
      of statin drugs in acute coronary syndrome (ACS). We investigated the effects of 
      atorvastatin therapy on plasma MCP-1 concentrations and production of MCP-1 
      released by peripheral blood monocytes from ACS patients. METHODS: Forty patients 
      with ACS were randomly separated into two groups, those receiving conventional 
      therapy (Group A, n=20), and conventional therapy+atorvastatin (10 mg/day, Group 
      B, n=20). The study the effects of atorvastatin on secretion and expression of 
      MCP-1, human peripheral blood monocytes from healthy donors were incubated with 
      atorvastatin (0.1-10 micromol/l) for up to 24 h in vitro. MCP-1 concentrations in 
      plasma and monocytes culture supernatants were measured by enzyme-linked 
      immunosorbent assays (ELISA). MCP-1 expression was measured by RT-PCR. RESULTS: 
      Plasma concentrations of MCP-1 were significantly lower after 4 weeks therapy in 
      both groups of patients [Group A from 97.4 (50.1-164) to 72.6 (36.3-156) pg/ml, 
      Group B from 101 (60-178) to 45 (29-91) pg/ml, (P<0.05, respectively)]. Compared 
      with conventional therapy alone, atorvastatin significantly further reduced 
      plasma MCP-1 concentrations. There was no significant correlation between the 
      degree of changes in plasma MCP-1 and LDL-C. In vitro, atorvastatin inhibits 
      production of MCP-1 up to 73%, in a concentration-dependent manner, and 
      suppressed MCP-1 expression in peripheral blood monocytes. CONCLUSIONS: 
      Atorvastatin reduced plasma MCP-1 concentrations in patients with ACS. These 
      effects may explain some clinical benefits of statins in the treatment of these 
      patients.
FAU - Xu, Zhu-mei
AU  - Xu ZM
AD  - Department of Cardiology, The Second XiangYa Hospital, Central South University, 
      Middle Ren-min Road No. 86, Hunan 410011, Changsha, People's Republic of China.
FAU - Zhao, Shui-ping
AU  - Zhao SP
FAU - Li, Quan-zhong
AU  - Li QZ
FAU - Nie, Sai
AU  - Nie S
FAU - Zhou, Hong-nian
AU  - Zhou HN
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Chemokine CCL2)
RN  - 0 (Culture Media, Conditioned)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Lipids)
RN  - 0 (Pyrroles)
RN  - 0 (RNA, Messenger)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
MH  - Atorvastatin
MH  - Cells, Cultured
MH  - Chemokine CCL2/analysis/*blood/genetics/metabolism
MH  - Coronary Disease/*blood/drug therapy/genetics/metabolism
MH  - Culture Media, Conditioned/chemistry
MH  - Female
MH  - Heptanoic Acids/*pharmacology/therapeutic use
MH  - Humans
MH  - Lipids/blood
MH  - Male
MH  - Middle Aged
MH  - Monocytes/drug effects/metabolism
MH  - Pyrroles/*pharmacology/therapeutic use
MH  - RNA, Messenger/genetics/metabolism
EDAT- 2003/11/26 05:00
MHDA- 2004/07/15 05:00
CRDT- 2003/11/26 05:00
PHST- 2003/11/26 05:00 [pubmed]
PHST- 2004/07/15 05:00 [medline]
PHST- 2003/11/26 05:00 [entrez]
AID - S0009898103003218 [pii]
AID - 10.1016/s0009-8981(03)00321-8 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2003 Dec;338(1-2):17-24. doi: 10.1016/s0009-8981(03)00321-8.